Efficacy and safety of weekly rifapentine and isoniazid for tuberculosis prevention in Chinese silicosis patients: a randomized controlled trial
Qiao-Ling Ruan, Xi-Tian Huang, Qing-Luan Yang, Xue-Feng Liu, Jing Wu, Ke-Chuan Pan, Yao-Jie Shen, Li-Min Cai, Qiao Ling, Tian Jiang, Jin-Jing Hong, Xiao-Dan Wang, Chun-Lian Ma, Guan-Qing Peng, Xiu-Zhen Wang, Jin-Chao Mao, Tian-Zhou Wu, Miao-Yao Lin, Ling-Yun Shao, Wen-Hong Zhang, Qiao-Ling Ruan, Xi-Tian Huang, Qing-Luan Yang, Xue-Feng Liu, Jing Wu, Ke-Chuan Pan, Yao-Jie Shen, Li-Min Cai, Qiao Ling, Tian Jiang, Jin-Jing Hong, Xiao-Dan Wang, Chun-Lian Ma, Guan-Qing Peng, Xiu-Zhen Wang, Jin-Chao Mao, Tian-Zhou Wu, Miao-Yao Lin, Ling-Yun Shao, Wen-Hong Zhang
Abstract
Objective: The aim was to evaluate the efficacy, safety and completion rate of 3-month, once-weekly rifapentine and isoniazid for tuberculosis (TB) prevention among Chinese silicosis patients.
Methods: Male silicosis patients without human immunodeficiency virus infection, aged 18 years to 65 years, with or without latent TB infection, were randomized 1:1 to receive rifapentine/isoniazid under direct observation (3RPT/INH group) or were untreated (observation group). Active TB incidence was compared between the two groups with 37 months of follow-up. Safety profile and complete rates were evaluated.
Results: A total of 1227 adults with silicosis were screened; 513 eligible participants were enrolled and assigned to 3RPT/INH (n = 254) vs. observation (n = 259). Twenty-eight participants were diagnosed with active TB, and 9 and 19 in the 3RPT/INH group and observation groups, respectively. In the intention-to-treat analysis, the cumulative active TB rate was 3.5% (9/254) in the 3RPT/INH group and 7.3% (19/259) in the observation group (log rank p 0.055). On per protocol analysis, the cumulative active TB rates were 0.7% (1/139) and 7.3% (19/259), respectively (log rank p 0.01). Owing to an unexpected high frequency of adverse events (70.4%) and Grade 3 or 4 AEs (7.9%), the completion rate of the 3RPT/INH regimen was 54.7% (139/254). Twenty-six (10.8%) participants had flu-like systemic drug reactions; five (2.1%) experienced hepatotoxicity.
Discussion: Weekly rifapentine/isoniazid prophylaxis prevented active TB among Chinese people with silicosis when taken, irrespective of LTBI screening; efficacy was reduced by lack of compliance. The regimen must be used with caution because of the high rates of adverse effects.
Clinical trial registration: ClinicalTrials.gov number: NCT02430259.
Keywords: Controlled clinical trial; Hepatoxicity; Isoniazid; Rifapentine; Systemic drug reactions; Tuberculosis.
Copyright © 2020. Published by Elsevier Ltd.
Source: PubMed